English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, November 22, 2021
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Friday, October 1, 2021
Edison Oncology和冠科美博(Apollomics)宣布EO1001(APL-122) I/IIa 期臨床試驗中首例患者接受治療
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
Edison Oncology和冠科美博(Apollomics)宣布EO1001(APL-122) I/IIa 期临床试验中首例患者接受治疗
Tuesday, August 10, 2021
冠科美博(APOLLOMICS)APL-102 中国I期临床研究完成首例患者给药
冠科美博(APOLLOMICS)APL-102 中國I期臨床研究完成首例患者給藥
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
Thursday, May 20, 2021
冠科美博上海分公司正式开业

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575